A new inhaler offering antibodies as a treatment for Covid infections will soon be available, according to researchers.
Augmenta Bioworks and TFF Pharmaceuticals announced in a joint release that the new technology will be an alternative to infusion treatments.
“We are very excited about these new data, which reinforce our view that AUG-3387 (the treatment) could represent an important new class of biologic-based treatment modalities that can effectively target the emerging and potentially more pathologic variants of the SARS-CoV-2 virus,” explains Dr. Christopher Emig of Augmenta Bioworks.
The AUG-3387 antibody has the ability to neutralize the Delta variant. The treatment can in its form of dry powder directly reach the lungs.
As of July 22, the Delta variant represented more than 80 percent of new Covid infections across the US.
